...
首页> 外文期刊>International Journal of Biosciences >Targeting dopamine liposome to brain using polysorbate 80 for parkinson disease
【24h】

Targeting dopamine liposome to brain using polysorbate 80 for parkinson disease

机译:使用聚山梨酯80将多巴胺脂质体靶向脑部治疗帕金森病

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The aim of the present study was to prepare and evaluate Dopamine (Dp) liposome using polysorbate 80 (PS80) which enabled the targeted delivery of drug across Blood Brain Barrier (BBB) in the effective treatment of Parkinson disease as L dopa drug conventionally used for Parkinson's disease produces "wearing off" adverse reactions. Dp loaded liposome were prepared with various concentration of PS80 by Rev erse Phase Evaporation technique. The formation of liposome was confirmed by scanning electron microscopy (SEM). The drug and the excipient compatibility was analysed by FTIR, DSC and XRD studies. FTIR indicated that there was no loss in chemical integrity of the drug upon fabrication into liposome. DSC and XRD results demonstrated that the drug was changed from the crystalline form to the amorphous form in the formulation. Among all the formulations, LSP4 showed higher Entrapment efficiency (EE) of 68% and increases the animal locomotion in psychopharmacological study (18.3%). Dp Liposomal formulation LSP4 could be a choice for dopamine delivery directly to brain for Parkinson treatment alternative to conventional use of L dopa thus preventing "wearing of e ffect.
机译:本研究的目的是使用聚山梨酯80(PS80)制备和评估多巴胺(Dp)脂质体,该药物能够跨血脑屏障(BBB)靶向递送药物,从而有效治疗帕金森氏病,因为传统上使用的L多巴药物帕金森氏病产生“消退”的不良反应。通过Reverse相蒸发技术,制备了具有各种浓度的PS80的Dp负载脂质体。通过扫描电子显微镜(SEM)确认脂质体的形成。通过FTIR,DSC和XRD研究分析了药物和赋形剂的相容性。 FTIR表明,制成脂质体后,该药物的化学完整性没有损失。 DSC和XRD结果表明该药物在制剂中从结晶形式变为无定形形式。在所有制剂中,LSP4在心理药理研究中显示出68%的更高包封率(EE),并增加了动物的运动能力(18.3%)。 Dp脂质体制剂LSP4可能是直接将多巴胺直接递送至大脑的一种选择,以替代常规使用L多巴的帕金森氏治疗,从而防止了“效果的磨损”。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号